2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Acute Myeloid Leukemia By FAB Classification
National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Acute Myeloid Leukemia By FAB Classification cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunomycin Wake Forest University Health Sciences | Phase 3 | BBB |
Idarubicin University of Nebraska | Phase 3 | BB |
Valspodar National Cancer Institute (NCI) | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS Roswell Park Cancer Institute | Phase 3 | BB |
Azacitidine guomei | Phase 2 | BB |
View all 49 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →